Deep dives, evidence grades, and clinical tools, all in one place.
Practice Signal
Continuous Levodopa and MS Infusions in Neurology
Neurology3 sources · Updated Aug 17, 2026
This review helps pharmacists evaluate where subcutaneous continuous levodopa and subcutaneous natalizumab fit in advanced Parkinson disease and multiple sclerosis, and what to monitor when patients transition from oral or intravenous routes.
Bottom Line
Subcutaneous continuous drug delivery, whether foslevodopa/foscarbidopa for Parkinson OFF time or subcutaneous natalizumab for multiple sclerosis, offers durable disease control or major operational and experience gains, shifting the pharmacist's role toward infusion-site care, dose reconciliation, and patient selection.
2.81 h
OFF reduction, ND0612 at 36 months
3.5 h
OFF reduction, ABBV-951 at 52 weeks
74%
chair-time cut, SC vs IV natalizumab
86%
patients preferred SC natalizumab
State of Play
Subcutaneous delivery is expanding across chronic neurologic disease, with foslevodopa/foscarbidopa now the first U.S. Food and Drug Administration (FDA)-approved 24-hour subcutaneous levodopa infusion for motor fluctuations and subcutaneous natalizumab established as an alternative to intravenous (IV) dosing in relapsing-remitting multiple sclerosis (RRMS). For advanced Parkinson disease (APD), continuous subcutaneous infusion (CSCI) durably reduces OFF time; for multiple sclerosis (MS), the subcutaneous (SC) route is an efficiency and experience play rather than an efficacy change. Both bodies of evidence are low-certainty and observational but internally consistent.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.
One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.